Debiopharm, H. Lee Moffitt Cancer Center & Research Institute deal

Debiopharm received exclusive, worldwide rights to develop and commercialize the institute's small molecule inhibitor of the interaction between Raf-1 ( CRAF, RAF) and retinoblastoma protein, now c...